title: Expression of novel surface antigens on early hematopoietic cells.
abstract: The purpose of this report is to demonstrate the expression of very recently identified surface antigens on CD34+ and AC133+ bone marrow (BM) cells. Coexpression analysis of AC133 and defined antigens on CD34+ BM cells revealed that the majority of the CD164+, CD135+, CD117+, CD38low, CD33+, and CD71low cells resides in the AC133+ population. In contrast, most of the CD10+ and CD19+ B cell progenitors and a fraction of the CD71high population are AC133-, indicating that CD34+AC133+ cells are enriched in primitive and myeloid progenitor cells, whereas CD34+AC133- cells mainly consist of B cell and late erythroid progenitors. This corresponds to the highly reduced percentage of CD10+ B cells and the absence of CD71high erythroid progenitors on AC133+ selected BM cells. A portion of 0.2-0.7% of the AC133+ selected cells do not coexpress CD34. These cells are very small and define a uniform CD71-, CD117-, CD10-, CD38low, CD135+, HLA-DRhigh, CD45+ population with unknown delineation. Four color analysis on CD34+CD38- BM cells revealed that virtually all of these primitive cells express AC133. Using an improved liposome-enhanced labeling technique for the staining of weakly expressed antigens, subsets of this population could be identified which express the angiopoietin receptors TIE (67.6%) and TEK (36.8%), the vascular endothelial growth factor receptors FLT1 (7%), FLT4 (3.2%), and KDR (10.4%), or the receptor tyrosine kinases HER-2 (15.4%) and FLT3 (CD135; 77.6%). Our results suggest that the CD34+CD38- population is heterogeneous with respect to the expression of the analyzed receptor tyrosine kinases.
authors.affiliation: Department of Hematology and Oncology, University of Tübingen, Germany. hjbuehri@med.uni-tuebingen.de
authors.forename: H J
authors.initials: HJ
authors.lastname: Bühring
authors.forename: M
authors.initials: M
authors.lastname: Seiffert
authors.forename: T A
authors.initials: TA
authors.lastname: Bock
authors.forename: S
authors.initials: S
authors.lastname: Scheding
authors.forename: A
authors.initials: A
authors.lastname: Thiel
authors.forename: A
authors.initials: A
authors.lastname: Scheffold
authors.forename: L
authors.initials: L
authors.lastname: Kanz
authors.forename: W
authors.initials: W
authors.lastname: Brugger
mesh_terms: D000071916:AC133 Antigen; D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D015703:Antigens, CD / Q000032:analysis*; D018952:Antigens, CD34 / Q000032:analysis*; D000943:Antigens, Differentiation / Q000032:analysis; D001402:B-Lymphocytes / Q000166:cytology / Q000276:immunology*; D001854:Bone Marrow Cells / Q000166:cytology* / Q000276:immunology; D002478:Cells, Cultured; D005434:Flow Cytometry; D006023:Glycoproteins / Q000032:analysis*; D006684:HLA-DR Antigens / Q000032:analysis; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000276:immunology*; D006801:Humans; D018189:Immunomagnetic Separation / Q000379:methods; D008562:Membrane Glycoproteins; D009244:NAD+ Nucleosidase / Q000032:analysis; D010455:Peptides / Q000032:analysis*; D020794:Receptor Protein-Tyrosine Kinases / Q000032:analysis
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D018952:Antigens, CD34; D000943:Antigens, Differentiation; D006023:Glycoproteins; D006684:HLA-DR Antigens; D008562:Membrane Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides; D020794:Receptor Protein-Tyrosine Kinases; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D009244:NAD+ Nucleosidase; D051997:ADP-ribosyl Cyclase 1